270 related articles for article (PubMed ID: 37733162)
21. Anti-Hypertensive Potential and Epigenetics of Angiotensin II type 2 Receptor (AT2R).
Chaudhary M
Curr Hypertens Rev; 2021; 17(3):176-180. PubMed ID: 33302839
[TBL] [Abstract][Full Text] [Related]
22. [The effect of ARB on prevention of atherosclerosis].
Aoyama T; Minatoguchi S
Nihon Rinsho; 2011 Jan; 69(1):92-9. PubMed ID: 21226267
[TBL] [Abstract][Full Text] [Related]
23. Within the Brain: The Renin Angiotensin System.
Jackson L; Eldahshan W; Fagan SC; Ergul A
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29543776
[TBL] [Abstract][Full Text] [Related]
24.
Ting R; Dutton H; Sorisky A
Adipocyte; 2023 Dec; 12(1):2194034. PubMed ID: 36973648
[TBL] [Abstract][Full Text] [Related]
25. The role of renin angiotensin system in the pathophysiology of rheumatoid arthritis.
Moreira FRC; de Oliveira TA; Ramos NE; Abreu MAD; Simões E Silva AC
Mol Biol Rep; 2021 Sep; 48(9):6619-6629. PubMed ID: 34417705
[TBL] [Abstract][Full Text] [Related]
26. Novel Cardiac Intracrine Mechanisms Based on Ang-(1-12)/Chymase Axis Require a Revision of Therapeutic Approaches in Human Heart Disease.
Reyes S; Varagic J; Ahmad S; VonCannon J; Kon ND; Wang H; Groban L; Cheng CP; Dell'Italia LJ; Ferrario CM
Curr Hypertens Rep; 2017 Feb; 19(2):16. PubMed ID: 28233239
[TBL] [Abstract][Full Text] [Related]
27. Renin-angiotensin system blockers affect cognitive decline in Parkinson's disease: The PPMI dataset.
Yang J; Gao Y; Duan Q; Qiu Y; Feng S; Zhan C; Huang Y; Zhang Y; Ma G; Nie K; Wang L
Parkinsonism Relat Disord; 2022 Dec; 105():90-95. PubMed ID: 36395543
[TBL] [Abstract][Full Text] [Related]
28. COVID-19 Therapeutics Why Not Angiotensin Receptor Blockers (ARBs)?
Hariharan TS
J Assoc Physicians India; 2023 Nov; 71(11):71-75. PubMed ID: 38720500
[TBL] [Abstract][Full Text] [Related]
29. Do angiotensin receptor blockers prevent Alzheimer's disease?
Hajjar I; Rodgers K
Curr Opin Cardiol; 2013 Jul; 28(4):417-25. PubMed ID: 23703253
[TBL] [Abstract][Full Text] [Related]
30. Angiotensin receptor blockers: evidence for preserving target organs.
Carson P; Giles T; Higginbotham M; Hollenberg N; Kannel W; Siragy HM
Clin Cardiol; 2001 Mar; 24(3):183-90. PubMed ID: 11288962
[TBL] [Abstract][Full Text] [Related]
31. Angiotensin II receptors: Impact for COVID-19 severity.
Aksoy H; Karadag AS; Wollina U
Dermatol Ther; 2020 Nov; 33(6):e13989. PubMed ID: 32645228
[TBL] [Abstract][Full Text] [Related]
32. Actions of Novel Angiotensin Receptor Blocking Drugs, Bisartans, Relevant for COVID-19 Therapy: Biased Agonism at Angiotensin Receptors and the Beneficial Effects of Neprilysin in the Renin Angiotensin System.
Moore GJ; Ridgway H; Kelaidonis K; Chasapis CT; Ligielli I; Mavromoustakos T; Bojarska J; Matsoukas JM
Molecules; 2022 Jul; 27(15):. PubMed ID: 35956801
[TBL] [Abstract][Full Text] [Related]
33. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.
Talbert RL
J Am Pharm Assoc (2003); 2010; 50(5):e116-25. PubMed ID: 20833609
[TBL] [Abstract][Full Text] [Related]
34. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.
Zhang Y; He D; Zhang W; Xing Y; Guo Y; Wang F; Jia J; Yan T; Liu Y; Lin S
Drugs; 2020 Jun; 80(8):797-811. PubMed ID: 32333236
[TBL] [Abstract][Full Text] [Related]
35. Renin Angiotensin Aldosterone System Inhibitors in Hypertension: Is There Evidence for Benefit Independent of Blood Pressure Reduction?
Bavishi C; Bangalore S; Messerli FH
Prog Cardiovasc Dis; 2016; 59(3):253-261. PubMed ID: 27777044
[TBL] [Abstract][Full Text] [Related]
36. Angiotensin II Type I Receptor (AT1R): The Gate towards COVID-19-Associated Diseases.
El-Arif G; Khazaal S; Farhat A; Harb J; Annweiler C; Wu Y; Cao Z; Kovacic H; Abi Khattar Z; Fajloun Z; Sabatier JM
Molecules; 2022 Mar; 27(7):. PubMed ID: 35408447
[TBL] [Abstract][Full Text] [Related]
37. ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective.
South AM; Brady TM; Flynn JT
Hypertension; 2020 Jul; 76(1):16-22. PubMed ID: 32367746
[TBL] [Abstract][Full Text] [Related]
38. Updates on the treatment of essential hypertension: a summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors.
Powers B; Greene L; Balfe LM
J Manag Care Pharm; 2011 Oct; 17(8 Suppl):S1-14. PubMed ID: 22088101
[TBL] [Abstract][Full Text] [Related]
39. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
Martin N; Manoharan K; Davies C; Lumbers RT
Cochrane Database Syst Rev; 2021 May; 5(5):CD012721. PubMed ID: 34022072
[TBL] [Abstract][Full Text] [Related]
40. Effects of ACE-inhibitors and angiotensin receptor blockers on inflammation.
Di Raimondo D; Tuttolomondo A; Buttà C; Miceli S; Licata G; Pinto A
Curr Pharm Des; 2012; 18(28):4385-413. PubMed ID: 22283779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
